Immune and respiratory support is the main area connected here, and any felt benefit should be read together with the human evidence base.
Some human supplement-context evidence is present and directly informs the score.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
10 new papers were added in this period. No new risk signal was identified.
Standalone side-effect signals and combination cautions are listed separately.
Paper IDs and full lists are private. Only study types and summaries are shown.
Vitamin D supplementation was safe and it protected against acute respiratory tract infection overall and patients who were very vitamin D deficient and those not receiving bolus doses experienced the most benefit.
Comparing vitamin D with placebo did not result in a lower incidence of invasive cancer or cardiovascular events than placebo, and Supplementation with vitamin D was not associated with a lower risk of either of the primary end points.
This study shows proof-of-principle that specific nutritional supplementation alone might benefit geriatric patients, especially relevant for those who are unable to exercise.
Among persons at high risk for type 2 diabetes not selected for vitamin D insufficiency, vitamin D3 supplementation at a dose of 4000 IU per day did not result in a significantly lower risk of diabetes than placebo.
It is suggested that vitamin D supplementation does not prevent fractures or falls, or have clinically meaningful effects on bone mineral density, and there is little justification to use vitamin D supplements to maintain or improve musculoskeletal health.
The findings suggest that vitamin D supplementation does not confer cardiovascular protection and is not indicated for this purpose.